Trial intelligence / Profile preview

Varenicline for relapse prevention in alcohol dependence (post-acute treatment)

2009-015537-67Phase 2Terminated

Sponsor
University Medical Center Mainz
Start
Oct 2009
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in alcohol dependence comparing Varenicline (Champix) with Placebo (2 arms). Primary endpoint: Percent of days abstinent from any alcohol during 12-week treatment. Started Oct 2009; status: terminated.

02

Drugs

varenicline
03

Conditions

alcohol dependence

Beyond the preview

Go deeper on 2009-015537-67.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-015537-67.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call